Divalproex Sodium Tablet, Delayed Release
NDC Package 68071-3553-6
Package Information
Divalproex Sodium tablets is divalproex sodium should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].Divalproex sodium is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].Divalproex sodium is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].Divalproex sodium is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].For use in prophylaxis of migraine headaches: Divalproex sodium is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]. This formulation utilizes a tablet, delayed release delivery system. Marketed by Nucare Pharmaceuticals,inc., this product is identified by NDC 68071-3553 and is authorized under FDA application ANDA078597.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68071 - Nucare Pharmaceuticals,inc.
- 68071-3553 - Divalproex Sodium
- 68071-3553-6 - 60 TABLET, DELAYED RELEASE in 1 BOTTLE
- 68071-3553 - Divalproex Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68071-3553-6 identifies a specific commercial package of 60 tablet, delayed release in 1 bottle of Divalproex Sodium, a human prescription drug labeled by Nucare Pharmaceuticals,inc.. This tablet, delayed release is formulated for oral use and contains divalproex sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nucare Pharmaceuticals,inc. on July 29, 2008. The current certification is valid through December 31, 2026.
How is this Nucare Pharmaceuticals,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68071355306. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.